Toggle light / dark theme

Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

The partnership will leverage OBT’s OGAP-Verify discovery platform, which claims to offer greater sensitivity and enables target selection with enhanced drug development attributes.


OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.